Skip to main content

Advertisement

Table 2 Study characteristics

From: Opinions on registering trial details: a survey of academic researchers

Variables Total E-mail available* E-mail not available p** Responders Non-responders p
Recruiting status of study 1500 1299 201 0.15 282 1017 0.68
   Recruiting 1375 (91.7) 1196 (92.1) 179 (89.0)   258 (91.5) 938 (92.23)  
   Not yet 125 (8.3) 103 (7.9) 125 (8.3)   24 (8.5) 79 (7.8)  
Type of sponsor     <0.001    <0.001
   NIH 288 (19.2) 207 (15.9) 81 (40.3)   21 (7.4) 186 (18.3)  
   Other 1212 (80.8) 1092 (84.1) 120 (59.7)   261 (92.5) 831 (81.7)  
Study condition according to ICD 10     <0.001    0.03
   Infections 69 (4.6) 64 (4.9) 5 (2.5)   22 (7.8) 42 (4.1)  
   Oncology 608 (40.5) 474 (36.5) 134 (66.7)   73 (25.9) 401 (39.4)  
   Haematology 23 (1.5) 19 (1.5) 4 (2.0)   3 (1.1) 16 (1.6)  
   Endocrinologic diseases 85 (5.7) 79 (6.1) 6 (3.0)   21 (7.4) 58 (5.7)  
   Psychiatric diseases 119 (7.9) 109 (8.4) 10 (4.9)   28 (9.9) 81 (8.0)  
   Neurologic diseases 62 (4.1) 58 (4.6) 4 (2.0)   14 (5.0) 44 (4.3)  
   Eye 12 (0.8) 2 (1.0) 10 (0.8)   2 (0.7) 8 (0.8)  
   Ear 2 (0.1) 2 (0.1) 0 (0.0)   1 (0.3) 1 (0.1)  
   Cardiovascular diseases 123 (8.2) 118 (9.1) 5 (2.5)   30 (10.6) 88 (8.6)  
   Lung diseases 59 (3.9) 53 (4.1) 6 (3.0)   10 (3.5) 43 (4.2)  
   Digestive diseases 43 (3.3) 4 (2.0) 47 (3.1)   15 (5.2) 28 (2.7)  
   Skin 19 (1.3) 18 (1.4) 1 (0.5)   3 (1.1) 15 (1.5)  
   Musculoskeletal disorders 51 (3.4) 48 (3.7) 3 (1.5)   12 (4.3) 36 (3.5)  
   Urology 76 (5.1) 72 (5.5) 4 (2.0)   20 (7.1) 52 (5.1)  
   Pregnancy 26 (1.7) 23 (1.8) 3 (1.5)   5 (1.8) 18 (1.8)  
   Perinatal disorders 10 (0.7) 10 (0.8) 0 (0.0)   3 (1.1) 7 (0.7)  
   Labour 2 (0.1) 2 (0.1) 0 (0.0)   1 (0.3) 1 (0.1)  
   Trauma 39 (2.6) 35 (2.7) 4 (2.0)   6 (2.1) 29 (2.8)  
   Extern 1 (0.1) 1 (0.1) 0 (0.0)   1 (0.3) 0 (0.0)  
   Other 67 (4.5) 61 (4.7) 6 (3.0)   12 (4.3) 49 (4.8)  
Study intervention     <0.001    0.10
   Drug 895 (59.7) 741 (57.0) 154 (76.6)   143 (50.7) 598 (58.8)  
   Procedure 231 (15.4) 211 (16.2) 20 (9.9)   55 (19.5) 156 (15.3)  
   Behaviour 112 (7.5) 107 (8.2) 5 (2.5)   32 (11.3) 75 (7.4)  
   Device 64 (4.3) 62 (4.8) 2 (1.0)   14 (5.0) 48 (4.7)  
   Vaccine 17 (1.1) 12 (0.9) 5 (2.5)   3 (1.1) 9 (0.9)  
   Gene therapy 5 (0.3) 4 (0.3) 1 (0.5)   0 (0.0) 4 (0.4)  
   Other/not applicable 176 (11.7) 162 (12.5) 14 (7.0)   35 (12.4) 127 (12.5)  
Study phase     <0.001    <0.01
   Phase I 137 (9.1) 113 (8.7) 24 (11.9)   19 (6.7) 94 (9.2)  
   Phase II 357 (23.8) 281 (21.6) 76 (37.8)   45 (16.0) 236 (23.2)  
   Phase III 230 (15.3) 206 (15.9) 24 (11.9)   51 (8.1) 155 (15.2)  
   Phase IV 177 (11.8) 168 (12.9) 9 (4.5)   48 (17.0) 120 (11.8)  
   Phase I/II 72 (4.8) 56 (4.3) 16 (8.0)   6 (2.1) 50 (4.9)  
   Phase II/III 43 (2.9) 35 (2.7) 8 (4.0)   6 (2.1) 29 (2.8)  
   Not applicable 484 (32.3) 440 (33.9) 44 (21.9)   107 (37.9) 333 (32.7)  
  1. * E-mail address of principal investigator
  2. ** Chi-squared test
  3. Categories with less than six counts overall were added to category "Other" or "Other/not applicable" for the chi-square test.